Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Cut by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,680 shares of the biopharmaceutical company’s stock after selling 33 shares during the period. Crossmark Global Holdings Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,354,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC raised its position in Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after acquiring an additional 669,517 shares in the last quarter. Capital World Investors boosted its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares in the last quarter. Northern Trust Corp increased its position in Regeneron Pharmaceuticals by 3.3% during the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after buying an additional 34,326 shares during the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $932,571,000. Finally, Morgan Stanley increased its holdings in shares of Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after acquiring an additional 25,792 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ REGN opened at $1,002.95 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $1,016.00. The firm’s 50-day moving average is $949.32 and its 200-day moving average is $927.00. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $110.52 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on REGN. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 target price for the company. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. UBS Group boosted their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Bank of America raised their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Finally, Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $989.86.

Get Our Latest Stock Analysis on REGN

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total value of $836,097.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,397,202. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 55,612 shares of company stock valued at $54,346,970 in the last quarter. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.